Skip Navigation
Search
Back to Search Innovations
Chemically Modified Curcumins (CMCs) Their Homolgues and Lower Analogues as Inhibitors of Matrix Metalloproteases (MMPs) and Pro-inflammatory Cytokkines (PICs)
Novel class of compound that display biological activities equal to or better than natural curcumin, which has been used throughout history to treat a wide variety of ailments.

Background

Curcumin, a principal biological compound in the popular Indian curry spice turmeric, has been used throughout history to treat a wide variety of skin, pulmonary, gastrointestinal system and liver diseases and conditions, as well as wounds. Today,numerous studies are starting to reveal why: curcumin acts as an antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal and anticancer agent. Unfortunately, curcumin is notoriously insoluble and tends to have a cytotoxic effect on human cells at low concentrations, disadvantages that greatly limit the clinical use of curcumin and its analogues.

Technology

Dr. Francis Johnson, professor in the Department of Chemistry and Pharmacological Sciences, and president of Chem-Masters International Inc., has synthesized a novel class of compound that displays biological activity that may be better than naturally-occurring curcumin. Dr. Lorne Golub, distinguished professor in the Department of Oral Biology and Pathology has used them as zinc binding agents to modulate human MMP expression, production and activity, as well as aberrantpro-inflammatory cytokine expression and harmful growth factor activity. Their research shows promise as a new treatment for connective tissue- and bone-destructive ailments, and inflammatory related diseases, including ARDS and rheumatoid arthritis.

Advantages

Superior biological properties and activity vs. curcumin in experimental models. Vastly improved solubility and bio availability. May improve pharmacokinetics.

Application

Novel therapeutic compounds Zinc binding MMP activity Cytokine inhibitor

Inventors

Lorne Golub, Distinguished Professor, Oral Biology and Pathology

Licensing Status

Other (See Additional Information)

Licensing Contact

Sean Boykevisch, Director, Intellectual Property Partners, sean.boykevisch@stonybrook.edu, 6316326952

Patent Status

PCT Publication No. WO 2010-132815

Animal and in-vitro data is available.

Tech Id

8134